Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FDQXX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,357
Award facts
- Contract value 100% obligated
- $11,357.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,357.40 by the Defense Logistics Agency on August 1, 2025. The contract calls for the delivery of NUCALA 100 mg/mL syringes, with an ultimate completion date of August 4, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a qualified supplier in the federal marketplace. The contract is performed at the vendor's location in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for military health facilities worldwide. NUCALA (mepolizumab) is a biologic medication used in respiratory disease treatment, reflecting the company's established role as a critical supplier of specialized pharmaceutical products to Department of Defense healthcare sites. The company's federal contracting history demonstrates consistent success in delivering branded and generic prescription drugs, biologics, and medical consumables to support military medical operations globally.
Quick answers
Who was awarded contract SPE2DB25FDQXX?
SPE2DB25FDQXX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 1, 2025.
How much is contract SPE2DB25FDQXX worth?
The government has obligated $11,357 on SPE2DB25FDQXX.
Is contract SPE2DB25FDQXX an order under another contract?
Yes. SPE2DB25FDQXX is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB25FDQXX competed?
The extent of competition for SPE2DB25FDQXX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award